Search Results

There are 43924 results for: content related to: A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder

  1. You have full text access to this OnlineOpen article
    A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine

    Human Psychopharmacology: Clinical and Experimental

    Volume 29, Issue 5, September 2014, Pages: 470–482, Stuart A. Montgomery, Rebecca Z. Nielsen, Lis H. Poulsen and Lars Häggström

    Version of Record online : 3 AUG 2014, DOI: 10.1002/hup.2424

  2. Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder

    Human Psychopharmacology: Clinical and Experimental

    Volume 28, Issue 3, May 2013, Pages: 258–262, Alissa J. Cooper, Karl Rickels and Falk W. Lohoff

    Version of Record online : 8 MAY 2013, DOI: 10.1002/hup.2317

  3. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder

    International Journal of Clinical Practice

    Volume 68, Issue 1, January 2014, Pages: 49–59, A. R. Mahableshwarkar, P. L. Jacobsen, Y. Chen and J. S. Simon

    Version of Record online : 17 DEC 2013, DOI: 10.1111/ijcp.12328

  4. Clinical evaluation of the efficacy and safety of tandospirone versus sertraline monotherapy for social anxiety disorder: a randomized open-label trial

    Human Psychopharmacology: Clinical and Experimental

    Volume 28, Issue 6, November 2013, Pages: 594–599, Xiao Huang, Chao Li, Wei-hui Li, Yan-li Luo, Biao Wang, Wei Zhang, Jian-jun Gan and Jian-lin Ji

    Version of Record online : 4 NOV 2013, DOI: 10.1002/hup.2361

  5. Inferring about individual drug and schizotypy effects on cognitive functioning in polydrug using mephedrone users before and after clubbing

    Human Psychopharmacology: Clinical and Experimental

    Volume 28, Issue 2, March 2013, Pages: 168–182, Daniela A. Herzig, Rowan Brooks and Christine Mohr

    Version of Record online : 27 MAR 2013, DOI: 10.1002/hup.2307

  6. Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate

    Human Psychopharmacology: Clinical and Experimental

    Volume 28, Issue 6, November 2013, Pages: 562–575, Alison Diaper, Ann S. Rich, Sue J. Wilson, Kevin Craig, Colin T. Dourish, Gerry R. Dawson, David J. Nutt and Jayne E. Bailey

    Version of Record online : 16 AUG 2013, DOI: 10.1002/hup.2346

  7. Longitudinal missing data strategies for substance use clinical trials using generalized estimating equations: an example with a buprenorphine trial

    Human Psychopharmacology: Clinical and Experimental

    Volume 28, Issue 5, September 2013, Pages: 506–515, Sterling McPherson, Celestina Barbosa-Leiker, Michael McDonell, Donelle Howell and John Roll

    Version of Record online : 9 SEP 2013, DOI: 10.1002/hup.2339

  8. You have free access to this content
    “Spiceophrenia”: a systematic overview of “Spice”-related psychopathological issues and a case report

    Human Psychopharmacology: Clinical and Experimental

    Volume 28, Issue 4, July 2013, Pages: 379–389, Duccio Papanti, Fabrizio Schifano, Giulia Botteon, Francesca Bertossi, Jason Mannix, Daniela Vidoni, Matteo Impagnatiello, Elisabetta Pascolo-Fabrici and Tommaso Bonavigo

    Version of Record online : 23 JUL 2013, DOI: 10.1002/hup.2312

  9. Psychological functioning 1 year after a brief intervention using micronutrients to treat stress and anxiety related to the 2011 Christchurch earthquakes: a naturalistic follow-up

    Human Psychopharmacology: Clinical and Experimental

    Volume 29, Issue 3, May 2014, Pages: 230–243, Julia J. Rucklidge, Neville Blampied, Brigette Gorman, Heather A. Gordon and Ellen Sole

    Version of Record online : 19 FEB 2014, DOI: 10.1002/hup.2392

  10. The potential role of atypical antipsychotics in the treatment of panic disorder

    Human Psychopharmacology: Clinical and Experimental

    Volume 29, Issue 5, September 2014, Pages: 405–413, Hee Ryung Wang, Young Sup Woo and Won-Myong Bahk

    Version of Record online : 9 JUL 2014, DOI: 10.1002/hup.2419

  11. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials.

    Human Psychopharmacology: Clinical and Experimental

    Volume 29, Issue 2, March 2014, Pages: 120–132, Consuelo García-Gea, Joan Martínez, Maria Rosa Ballester, Ignasi Gich, Román Valiente and Rosa Maria Antonijoan

    Version of Record online : 3 JAN 2014, DOI: 10.1002/hup.2378

  12. Computer-aided (in silico) approaches in the mode-of-action analysis and safety assessment of Ostarine and 4-methylamphetamine

    Human Psychopharmacology: Clinical and Experimental

    Volume 28, Issue 4, July 2013, Pages: 365–378, Fazlin Mohd Fauzi, Alexios Koutsoukas, Andrew Cunningham, Ana Gallegos, Roumen Sedefov and Andreas Bender

    Version of Record online : 23 JUL 2013, DOI: 10.1002/hup.2322

  13. Salvia divinorum: from Mazatec medicinal and hallucinogenic plant to emerging recreational drug

    Human Psychopharmacology: Clinical and Experimental

    Volume 28, Issue 5, September 2013, Pages: 403–412, Jolanta B. Zawilska and Jakub Wojcieszak

    Version of Record online : 23 JUN 2013, DOI: 10.1002/hup.2304

  14. Patterns of atypical antipsychotic therapy use in adults with bipolar I disorder in the USA

    Human Psychopharmacology: Clinical and Experimental

    Volume 28, Issue 5, September 2013, Pages: 428–437, Wenjia Chen, Angela M. DeVeaugh-Geiss, Liisa Palmer, Nicole Princic and Ya-Ting Chen

    Version of Record online : 17 JUL 2013, DOI: 10.1002/hup.2326

  15. Novel pharmacological agents targeting memory and cognition in the treatment of anxiety disorders

    Human Psychopharmacology: Clinical and Experimental

    Volume 28, Issue 6, November 2013, Pages: 538–543, Harpal Singh Nandhra, Catherine Louise Murphy and Akeem Sule

    Version of Record online : 29 AUG 2013, DOI: 10.1002/hup.2348

  16. MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblin et al. (2014)

    Human Psychopharmacology: Clinical and Experimental

    Volume 29, Issue 2, March 2014, Pages: 109–119, Andrew C. Parrott

    Version of Record online : 3 MAR 2014, DOI: 10.1002/hup.2390

  17. Attitude towards second-generation antipsychotics among patients with schizophrenia and their relatives

    Human Psychopharmacology: Clinical and Experimental

    Volume 28, Issue 5, September 2013, Pages: 457–465, MS Karthik, Parmanand Kulhara and Subho Chakrabarti

    Version of Record online : 20 JUN 2013, DOI: 10.1002/hup.2332

  18. Evaluation of the safety, pharmacodynamic, and pharmacokinetic effects following oral coadministration of immediate-release morphine with ethanol in healthy male participants

    Human Psychopharmacology: Clinical and Experimental

    Volume 29, Issue 3, May 2014, Pages: 251–265, Beatrice Setnik, Marta Sokolowska, Franklin Johnson, John Oldenhof and Myroslava Romach

    Version of Record online : 13 MAR 2014, DOI: 10.1002/hup.2394

  19. You have free access to this content
    Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research

    Human Psychopharmacology: Clinical and Experimental

    Volume 28, Issue 4, July 2013, Pages: 289–307, Andrew C. Parrott

    Version of Record online : 23 JUL 2013, DOI: 10.1002/hup.2318

  20. A meta-analysis of inositol for depression and anxiety disorders

    Human Psychopharmacology: Clinical and Experimental

    Volume 29, Issue 1, January 2014, Pages: 55–63, Tomohiko Mukai, Taro Kishi, Yuki Matsuda and Nakao Iwata

    Version of Record online : 3 DEC 2013, DOI: 10.1002/hup.2369